ScreenerHero

BMRN BioMarin Pharmaceutical Inc. - Common Stock

NAS · US · Healthcare · Biotechnology · biomarin.com
56.85USD-0.58%Mkt Cap: 11.07B $P/E: 154.54

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap11.07B USD
Enterprise Value14.40B USD
Revenue (TTM)3.41B USD
Gross Profit2.50B USD
Net Income (TTM)348.90M USD
Revenue/Share17.69 USD
Last Price56.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)154.54
P/E (Forward)8.64
PEG0.33
EV/EBITDA22.31
EV/Revenue4.23
P/S3.25
P/B1.75
EPS (TTM)0.37
EPS (Forward)6.62
52W Range
49.2635% of range70.98
52W High70.98 USD
52W Low49.26 USD
Profitability
Gross Margin77.73%
Oper. Margin21.16%
EBITDA Margin18.94%
Profit Margin10.83%
ROE5.73%
ROA4.59%
Growth
Revenue Growth19.90%
Earnings Growth-81.30%
Cash Flow & Leverage
Operating CF827.99M USD
CapEx (TTM)110.97M USD
FCF Margin2.50%
FCF Yield0.77%
Net Debt3.33B USD
Net Debt/EBITDA5.16
Balance Sheet
Debt/Equity0.10
Current Ratio2.39
Quick Ratio1.16
Book Value/Sh32.66 USD
Cash/Share4.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)91.62 USD
Upside (mean)+61.2%
Target Range60.00 USD – 124.00 USD
60.00+61.2% to mean124.00
# Analysts26
Ownership
Shares Out.193.57M
Float192.63M
Insiders0.34%
Institutions103.52%
Short Interest
Short Ratio5.6d
Short % Float5.22%
Short % Out.5.21%
Shares Short10.08M
Short (prev mo.)10.20M
Technical
SMA 5063.98 (-11.2%)
SMA 20058.67 (-3.1%)
Beta0.24
S&P 52W Chg14.58%
Avg Vol (30d)2.00M
Avg Vol (10d)1.96M
Technical Indicators
RSI (14)28.9
MACD-1.5252
MACD Signal-0.7317
MACD Hist.-0.7935
BB Upper69.05 USD
BB Middle63.06 USD
BB Lower57.06 USD
BB Width19.02%
ATR (14)1.646 USD
Vol Ratio (20d)1.08x